Dasatinib

Overview

Dasatinib is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with Philadelphia chromosome-positive (Ph+). It works by inhibiting the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality.

API suppliers (8)

Suppliers of Dasatinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Granules India LimitedIndia2 active DMF
• Hetero Labs LimitedIndia2 active DMF
• MSN Laboratories Private LimitedIndia2 active DMF
• TAPI NL BV2 active DMF
• Kisun Pharmaceutical Co., Ltd.China2 active DMF
• Cipla USA, Inc.USA2 active DMF
• Sichuan Baili Pharmaceutical Co., Ltd.China1 active DMF
• Zhejiang Hisun Pharmaceutical Co., Ltd.China

Patent & exclusivity (US)

Per the FDA Orange Book (60 approved US products), the latest listed US patent on Dasatinib expires 22 Jan 2041 and exclusivity 5 Dec 2026. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide

Canonical SMILES

CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

InChIKey

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

Therapeutic areas